174 related articles for article (PubMed ID: 11602522)
21. Pharmacokinetic profile of amifostine.
Shaw LM; Bonner H; Lieberman R
Semin Oncol; 1996 Aug; 23(4 Suppl 8):18-22. PubMed ID: 8783662
[TBL] [Abstract][Full Text] [Related]
22. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236
[TBL] [Abstract][Full Text] [Related]
23. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Links M; Lewis C
Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
[TBL] [Abstract][Full Text] [Related]
24. Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model.
Symon Z; Levi M; Ensminger WD; Smith DE; Lawrence TS
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):473-8. PubMed ID: 11380236
[TBL] [Abstract][Full Text] [Related]
25. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug.
Calabro-Jones PM; Aguilera JA; Ward JF; Smoluk GD; Fahey RC
Cancer Res; 1988 Jul; 48(13):3634-40. PubMed ID: 2837319
[TBL] [Abstract][Full Text] [Related]
26. Localized Delivery of Amifostine Enhances Salivary Gland Radioprotection.
Varghese JJ; Schmale IL; Mickelsen D; Hansen ME; Newlands SD; Benoit DSW; Korshunov VA; Ovitt CE
J Dent Res; 2018 Oct; 97(11):1252-1259. PubMed ID: 29634396
[TBL] [Abstract][Full Text] [Related]
27. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action.
Grdina DJ; Shigematsu N; Dale P; Newton GL; Aguilera JA; Fahey RC
Carcinogenesis; 1995 Apr; 16(4):767-74. PubMed ID: 7728953
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of amifostine and its metabolites in patients.
Korst AE; Eeltink CM; Vermorken JB; van der Vijgh WJ
Eur J Cancer; 1997 Aug; 33(9):1425-9. PubMed ID: 9337685
[TBL] [Abstract][Full Text] [Related]
29. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
30. A review of the use of chemoprotectants in cancer chemotherapy.
Lewis C
Drug Saf; 1994 Sep; 11(3):153-62. PubMed ID: 7811398
[TBL] [Abstract][Full Text] [Related]
31. Radioprotectants: pharmacology and clinical applications of amifostine.
Dorr RT
Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):10-3. PubMed ID: 9794995
[TBL] [Abstract][Full Text] [Related]
32. Future development of amifostine as a radioprotectant.
Werner-Wasik M
Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
[TBL] [Abstract][Full Text] [Related]
33. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
34. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
[TBL] [Abstract][Full Text] [Related]
35. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
Shaw LM; Bonner HS; Brown DQ
Drug Metab Dispos; 1994; 22(6):895-902. PubMed ID: 7895607
[TBL] [Abstract][Full Text] [Related]
36. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion.
Bonner HS; Shaw LM
J Clin Pharmacol; 2002 Feb; 42(2):166-74. PubMed ID: 11831539
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of spontaneous metastases formation by amifostine.
Grdina DJ; Kataoka Y; Murley JS; Hunter N; Weichselbaum RR; Milas L
Int J Cancer; 2002 Jan; 97(2):135-41. PubMed ID: 11774255
[TBL] [Abstract][Full Text] [Related]
38. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):794-802. PubMed ID: 14529786
[TBL] [Abstract][Full Text] [Related]
39. Amifostine (Ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: results of a phase I study.
Fiorentini G; Giovanis P; Leoni M; De Giorgi U; Cariello A; Dazzi C; Caldeo A
Hepatogastroenterology; 2001; 48(38):313-6. PubMed ID: 11379297
[TBL] [Abstract][Full Text] [Related]
40. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]